KMT2D and cancer: Conversely, Kmt2d deficiency was variably associated with a lack of cancer development or with the development of non-GC aggressive lymphomas, depending on inactivation strategy, i.e. Cγ1creKmt2dfl/fl mice (81) or CD19creKmt2dfl/fl mice (80), respectively.